BRAF and melanoma: The improvement of survival outcomes in patients with advanced melanoma due to the introduction of immune checkpoint inhibitors (ICIs) and targeted therapy (TT) for BRAF mutated melanoma, is undoubtedly very remarkable; nevertheless a proportion of patients still have poor prognosis [1–3].